OCUGEN, INC. Fair Value Adjustment of Warrants
OCUGEN, INC. (OCGN) reported Fair Value Adjustment of Warrants of $5.00 thousand for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-08-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2019-08-09
- OCUGEN, INC. fair value adjustment of warrants for the quarter ending 2019-06-30 was $5.00K.
- OCUGEN, INC. fair value adjustment of warrants for the quarter ending 2019-03-31 was $1.41M, a 83.93% decline year-over-year.
- OCUGEN, INC. fair value adjustment of warrants for the quarter ending 2018-12-31 was -$8.08M, a 1098.39% decline year-over-year.
- OCUGEN, INC. fair value adjustment of warrants for the quarter ending 2018-09-30 was -$17.78M, a 6708.18% decline year-over-year.
- OCUGEN, INC. fair value adjustment of warrants for fiscal 2018 was -$20.60M, a 1490.08% decline from fiscal 2017.
- OCUGEN, INC. fair value adjustment of warrants for fiscal 2017 was $1.48M.
- OCUGEN, INC. fair value adjustment of warrants for fiscal 2016 was -$17.51M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2019-06-30 | $5.00K 10-Q · filed 2019-08-09 | $1.41M 10-Q · filed 2019-08-09 | -$6.67M derived: sum of 3 quarters · filed 2019-08-09 | -$24.44M derived: sum of 4 quarters · filed 2019-08-09 |
| 2019-03-31 | $1.41M 10-Q · filed 2019-05-15 | -$6.67M derived: sum of 2 quarters · filed 2019-05-15 | -$24.45M derived: sum of 3 quarters · filed 2019-05-15 | -$27.95M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-12-31 | -$8.08M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | -$25.85M derived: sum of 2 quarters · filed 2019-03-22 | -$29.35M derived: sum of 3 quarters · filed 2019-08-09 | -$20.60M 10-K · filed 2019-03-22 |
| 2018-09-30 | -$17.78M 10-Q · filed 2018-11-08 | -$21.28M derived: sum of 2 quarters · filed 2019-08-09 | -$12.52M 10-Q · filed 2018-11-08 | -$11.71M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-06-30 | -$3.50M 10-Q · filed 2019-08-09 | $5.25M 10-Q · filed 2019-08-09 | $6.06M derived: sum of 3 quarters · filed 2019-08-09 | $6.33M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $8.75M 10-Q · filed 2019-05-15 | $9.56M derived: sum of 2 quarters · filed 2019-05-15 | $9.83M derived: sum of 3 quarters · filed 2019-05-15 | $9.97M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $809.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $1.08M derived: sum of 2 quarters · filed 2019-03-22 | $1.21M derived: sum of 3 quarters · filed 2019-03-22 | $1.48M 10-K · filed 2019-03-22 |
| 2017-09-30 | $269.00K 10-Q · filed 2018-11-08 | $404.00K derived: sum of 2 quarters · filed 2018-11-08 | $673.00K 10-Q · filed 2018-11-08 | -$16.30M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $135.00K 10-Q · filed 2018-08-09 | $404.00K 10-Q · filed 2018-08-09 | -$16.56M derived: sum of 3 quarters · filed 2018-08-09 | -$17.10M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $269.00K 10-Q · filed 2018-05-10 | -$16.70M derived: sum of 2 quarters · filed 2018-05-10 | -$17.24M derived: sum of 3 quarters · filed 2018-05-10 | |
| 2016-12-31 | -$16.97M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$17.51M derived: sum of 2 quarters · filed 2018-03-15 | -$17.51M 10-K · filed 2018-03-15 | |
| 2016-09-30 | -$539.00K 10-Q · filed 2017-11-09 | -$539.00K 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |